Search

Your search keyword '"Gelson, William"' showing total 198 results
Start Over Author "Gelson, William"
198 results on '"Gelson, William"'

1. Distinct virologic trajectories in chronic hepatitis B identify heterogeneity in response to nucleos(t)ide analogue therapy

Author

Barnes, Eleanor, Matthews, Philippa C., Gelson, William, Cooke, Graham S., Khakoo, Salim I., Nastouli, Eleni, Davies, Jim, Woods, Kerrie, Stockdale, Alexander J., Ryder, Stephen, Elsharkawy, Ahmed, Easom, Nicholas, Bernal, William, Ahmad, Shazaad, Macdonald, Douglas, Wang, Tingyan, Campbell, Cori, Stanworth, Simon, Maynard, Suzanne, Roadknight, Gail, Little, Stephanie, Várnai, Kinga A., Glampson, Ben, Papadimitriou, Dimitri, Mercuri, Luca, Jones, Christopher R., Jaworski, Jakub, Davis, Cai, Borca, Florina, Heinson, Ashley, George, Michael, MacNaughton, Heidi, Kim, Yun, Meneses, Josune Olza, English, Louise, Roberts, Timothy, Romão, Luis, Ramlakhan, David, Todd, Stacy, Rogers, Heather, McIntyre, Karl, Frankland, Andrew, Salih, Hizni, Noble, Theresa, Roberts, Lara, Higgins, Finola, Vilar, Javier, Norris, Ruth, Tilston, George, Serafimova, Ilina, Montague, Sarah, Verheyden, Juliette, Juurlink, Irene, Jack, Kathryn, Waldren-Glenn, Alex, Poole, Lizzie, Day, Victoria, Reglar, Berit, Mayer, Erik, and Heinson, Ashley I.

Published
2024
Full Text
View/download PDF

2. FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2

Author

Brevini, Teresa, Maes, Mailis, Webb, Gwilym J., John, Binu V., Fuchs, Claudia D., Buescher, Gustav, Wang, Lu, Griffiths, Chelsea, Brown, Marnie L., Scott, III, William E., Pereyra-Gerber, Pehuén, Gelson, William T. H., Brown, Stephanie, Dillon, Scott, Muraro, Daniele, Sharp, Jo, Neary, Megan, Box, Helen, Tatham, Lee, Stewart, James, Curley, Paul, Pertinez, Henry, Forrest, Sally, Mlcochova, Petra, Varankar, Sagar S., Darvish-Damavandi, Mahnaz, Mulcahy, Victoria L., Kuc, Rhoda E., Williams, Thomas L., Heslop, James A., Rossetti, Davide, Tysoe, Olivia C., Galanakis, Vasileios, Vila-Gonzalez, Marta, Crozier, Thomas W. M., Bargehr, Johannes, Sinha, Sanjay, Upponi, Sara S., Fear, Corrina, Swift, Lisa, Saeb-Parsy, Kourosh, Davies, Susan E., Wester, Axel, Hagström, Hannes, Melum, Espen, Clements, Darran, Humphreys, Peter, Herriott, Jo, Kijak, Edyta, Cox, Helen, Bramwell, Chloe, Valentijn, Anthony, Illingworth, Christopher J. R., Dahman, Bassam, Bastaich, Dustin R., Ferreira, Raphaella D., Marjot, Thomas, Barnes, Eleanor, Moon, Andrew M., Barritt, IV, Alfred S., Gupta, Ravindra K., Baker, Stephen, Davenport, Anthony P., Corbett, Gareth, Gorgoulis, Vassilis G., Buczacki, Simon J. A., Lee, Joo-Hyeon, Matheson, Nicholas J., Trauner, Michael, Fisher, Andrew J., Gibbs, Paul, Butler, Andrew J., Watson, Christopher J. E., Mells, George F., Dougan, Gordon, Owen, Andrew, Lohse, Ansgar W., Vallier, Ludovic, and Sampaziotis, Fotios

Published
2023
Full Text
View/download PDF

3. Liver transplantation for isolated unresectable colorectal liver metastases - Protocol for a service evaluation in the United Kingdom - UKCoMET study

Author

Adair, Anya, Parker, Ian, Berkman, Lindy, Gelson, William, Jones, Rebecca, Manas, Derek, Middleton, Gary, Murphy, Jamie, Peddu, Praveen, Isaac, John, Perera, Thamara, Prasad, Raj, Pollok, Joerg, Scarsbrook, Andrew, Zen, Yoh, Menon, Krishna, Vijayashanker, Aarathi, Line, Pål-Dag, and Thorburn, Douglas

Published
2023
Full Text
View/download PDF

4. FRI-374-YI The UK experience of liver transplantation for HBV: excellent clinical outcomes despite a significant burden of HBV/Delta disease and wide variation in hepatitis B immunoglobulin prophylaxis practices-time for a consistent approach?

Author

Mohamed, Almuthana, primary, Veloz, Maria Guerra, additional, François, Silke, additional, Botterill, Gemma, additional, Smith, Rachel, additional, Salman, Muhammad, additional, Greenland, Lindsay, additional, Turner, Lucy, additional, McPherson, Stuart, additional, Bathgate, Andrew, additional, Thorburn, Douglas, additional, Gelson, William, additional, Aldersley, Mark, additional, Elsharkawy, Ahmed M., additional, and Agarwal, Kosh, additional

Published
2024
Full Text
View/download PDF

5. TOP-417 Machine learning can improve prediction of hepatitis B surface antigen seroclearance: A large multicentre cohort study in the United Kingdom

Author

Wang, Tingyan, primary, Jaworski, Jakub, additional, Glampson, Ben, additional, Papadimitriou, Dimitri, additional, Mercuri, Luca, additional, Jones, Christopher R., additional, Todd, Stacy, additional, McIntyre, Karl, additional, Frankland, Andrew, additional, Salih, Hizni, additional, Roadknight, Gail, additional, Little, Stephanie, additional, Noble, Theresa, additional, Várnai, Kinga A., additional, Campbell, Cori, additional, Davis, Cai, additional, Heinson, Ashley I., additional, George, Michael, additional, Borca, Florina, additional, English, Louise, additional, Romão, Luis, additional, Ramlakhan, David, additional, Frisby, William, additional, Taylor, John, additional, Woods, Kerrie, additional, Davies, Jim, additional, Nastouli, Eleni, additional, Khakoo, Salim I., additional, Stockdale, Alexander J., additional, Easom, Nicholas, additional, Cooke, Graham S., additional, Gelson, William, additional, Matthews, Philippa C., additional, and Barnes, Eleanor, additional

Published
2024
Full Text
View/download PDF

6. WED-471 Retrospective analysis of longitudinal data for UK adults living with chronic HBV: characteristics of the population on dual therapy

Author

Tan, Cedric, primary, Wang, Tingyan, additional, Jaworski, Jakub, additional, Glampson, Ben, additional, Papadimitriou, Dimitri, additional, Mercuri, Luca, additional, Jones, Christopher R, additional, Todd, Stacy, additional, McIntyre, Karl, additional, Frankland, Andrew, additional, Salih, Hizni, additional, Roadknight, Gail, additional, Little, Stephanie, additional, Noble, Theresa, additional, AVárnai, Kinga, additional, Campbell, Cori, additional, Davis, Cai, additional, Heinson, Ashley I, additional, George, Michael, additional, Borca, Florina, additional, English, Louise, additional, Romão, Luis, additional, Ramlakhan, David, additional, Frisby, William, additional, Taylor, John, additional, Woods, Kerrie, additional, Davies, Jim, additional, Nastouli, Eleni, additional, Khakoo, Salim I, additional, Stockdale, Alexander J, additional, Easom, Nicholas, additional, Cooke, Graham S, additional, Gelson, William, additional, Barnes, Eleanor, additional, and CMatthews, Philippa, additional

Published
2024
Full Text
View/download PDF

7. Impact of the COVID-19 pandemic on routine surveillance for adults with chronic hepatitis B virus (HBV) infection in the UK

Author

Campbell, Cori, primary, Wang, Tingyan, additional, Smith, David A., additional, Freeman, Oliver, additional, Noble, Theresa, additional, Várnai, Kinga A, additional, Harris, Steve, additional, Salih, Hizni, additional, Roadknight, Gail, additional, Little, Stephanie, additional, Glampson, Ben, additional, Mercuri, Luca, additional, Papadimitriou, Dimitri, additional, Jones, Christopher R, additional, Taylor, Vince, additional, Chaudhry, Afzal, additional, Phan, Hang, additional, Borca, Florina, additional, Olza, Josune, additional, Warricker, Frazer, additional, Romão, Luis, additional, Ramlakhan, David, additional, English, Louise, additional, Klenerman, Paul, additional, Andersson, Monique I., additional, Collier, Jane, additional, Nastouli, Eleni, additional, Khakoo, Salim I., additional, Gelson, William, additional, Cooke, Graham S., additional, Woods, Kerrie, additional, Davies, Jim, additional, Barnes, Eleanor, additional, and Matthews, Philippa C., additional

Published
2023
Full Text
View/download PDF

11. Mortality rates among patients successfully treated for hepatitis C in the era of interferon-free antivirals: population based cohort study

Author

Hamill, Victoria, primary, Wong, Stanley, additional, Benselin, Jennifer, additional, Krajden, Mel, additional, Hayes, Peter C, additional, Mutimer, David, additional, Yu, Amanda, additional, Dillon, John F, additional, Gelson, William, additional, Velásquez García, Hector A, additional, Yeung, Alan, additional, Johnson, Philip, additional, Barclay, Stephen T, additional, Alvarez, Maria, additional, Toyoda, Hidenori, additional, Agarwal, Kosh, additional, Fraser, Andrew, additional, Bartlett, Sofia, additional, Aldersley, Mark, additional, Bathgate, Andy, additional, Binka, Mawuena, additional, Richardson, Paul, additional, Morling, Joanne R, additional, Ryder, Stephen D, additional, MacDonald, Douglas, additional, Hutchinson, Sharon, additional, Barnes, Eleanor, additional, Guha, Indra Neil, additional, Irving, William L, additional, Janjua, Naveed Z, additional, and Innes, Hamish, additional

Published
2023
Full Text
View/download PDF

13. Moving from non-emergency bleeps and long-range pagers to a hospital-wide, EHR-integrated secure messaging system: an implementer report

Author

Ercole, Ari, Tolliday, Claire, Gelson, William, Rudd, James HF, Cameron, Ewen, Chaudhry, Afzal, Hamer, Fiona, Davies, Justin, Ercole, Ari [0000-0001-8350-8093], and Apollo - University of Cambridge Repository

Subjects
Tertiary Care Centers, Electronic Health Records, Humans, Patient Safety, Information Technology, State Medicine
Abstract

INTRODUCTION: Obsolete bleep/long-range pager equipment remains firmly embedded in the National Health Service (NHS). OBJECTIVE: To introduce a secure, chart-integrated messaging system (Epic Secure Chat) in a large NHS tertiary referral centre to replace non-emergency bleeps/long-range pagers. METHODS: The system was socialised in the months before go-live. Operational readiness was overseen by an implementation group with stakeholder engagement. Cutover was accompanied by a week of Secure Chat and bleeps running in parallel. RESULTS: Engagement due to socialisation was high with usage stabilising approximately 3 months after go-live. Contact centre internal call activity fell significantly after go-live. No significant patient safety concerns were reported. DISCUSSION: Uptake was excellent with substantial utilisation well before cutover indirectly supporting high levels of engagement. The majority of those who previously carried bleeps were content to use personal devices for messaging because of user convenience after reassurance about privacy. CONCLUSION: An integrated secure messaging system can replace non-emergency bleeps with beneficial impact on service.

Published
2023

14. Liver transplantation for isolated unresectable colorectal liver metastases - Protocol for a service evaluation in the United Kingdom - UKCoMET study

Author

Menon, Krishna, primary, Vijayashanker, Aarathi, additional, Murphy, Jamie, additional, Line, Pål-Dag, additional, Isaac, John, additional, Adair, Anya, additional, Prasad, Raj, additional, Thorburn, Douglas, additional, Parker, Ian, additional, Berkman, Lindy, additional, Gelson, William, additional, Jones, Rebecca, additional, Manas, Derek, additional, Middleton, Gary, additional, Peddu, Praveen, additional, Perera, Thamara, additional, Pollok, Joerg, additional, Scarsbrook, Andrew, additional, and Zen, Yoh, additional

Published
2023
Full Text
View/download PDF

15. FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2

Author

Brevini, Teresa, Maes, Mailis, Webb, Gwilym J, John, Binu V, Fuchs, Claudia D, Buescher, Gustav, Wang, Lu, Griffiths, Chelsea, Brown, Marnie L, Scott, William E, Pereyra-Gerber, Pehuén, Gelson, William TH, Brown, Stephanie, Dillon, Scott, Muraro, Daniele, Sharp, Jo, Neary, Megan, Box, Helen, Tatham, Lee, Stewart, James, Curley, Paul, Pertinez, Henry, Forrest, Sally, Mlcochova, Petra, Varankar, Sagar S, Darvish-Damavandi, Mahnaz, Mulcahy, Victoria L, Kuc, Rhoda E, Williams, Thomas L, Heslop, James A, Rossetti, Davide, Tysoe, Olivia C, Galanakis, Vasileios, Vila-Gonzalez, Marta, Crozier, Thomas WM, Bargehr, Johannes, Sinha, Sanjay, Upponi, Sara S, Fear, Corrina, Swift, Lisa, Saeb-Parsy, Kourosh, Davies, Susan E, Wester, Axel, Hagström, Hannes, Melum, Espen, Clements, Darran, Humphreys, Peter, Herriott, Jo, Kijak, Edyta, Cox, Helen, Bramwell, Chloe, Valentijn, Anthony, Illingworth, Christopher, UK-PBC Consortium, Dahman, Bassam, Bastaich, Dustin R, Ferreira, Raphaella D, Marjot, Thomas, Barnes, Eleanor, Moon, Andrew M, Barritt, Alfred S, Gupta, Ravindra K, Baker, Stephen, Davenport, Anthony P, Corbett, Gareth, Gorgoulis, Vassilis G, Buczacki, Simon JA, Lee, Joo-Hyeon, Matheson, Nicholas J, Trauner, Michael, Fisher, Andrew J, Gibbs, Paul, Butler, Andrew J, Watson, Christopher JE, Mells, George F, Dougan, Gordon, Owen, Andrew, Lohse, Ansgar W, Vallier, Ludovic, Sampaziotis, Fotios, Brevini, Teresa [0000-0002-3581-5379], Maes, Mailis [0000-0002-0266-6557], Wang, Lu [0000-0002-4418-8602], Brown, Marnie L [0000-0001-6463-0288], Scott, William E [0000-0003-1515-0514], Sharp, Jo [0000-0001-8482-5736], Neary, Megan [0000-0002-4960-2139], Tatham, Lee [0000-0001-9448-8876], Stewart, James [0000-0002-8928-2037], Darvish-Damavandi, Mahnaz [0000-0003-0226-2621], Williams, Thomas L [0000-0002-1051-0595], Crozier, Thomas WM [0000-0003-0951-4588], Bargehr, Johannes [0000-0002-9304-3573], Sinha, Sanjay [0000-0001-5900-1209], Saeb-Parsy, Kourosh [0000-0002-0633-3696], Wester, Axel [0000-0003-3634-6591], Melum, Espen [0000-0001-6903-6878], Bramwell, Chloe [0000-0001-8274-457X], Barnes, Eleanor [0000-0002-0860-0831], Moon, Andrew M [0000-0001-7163-2062], Gupta, Ravindra K [0000-0001-9751-1808], Baker, Stephen [0000-0003-1308-5755], Davenport, Anthony P [0000-0002-2096-3117], Gorgoulis, Vassilis G [0000-0001-9001-4112], Buczacki, Simon JA [0000-0002-2975-416X], Lee, Joo-Hyeon [0000-0002-7364-6422], Matheson, Nicholas J [0000-0002-3318-1851], Trauner, Michael [0000-0002-1275-6425], Fisher, Andrew J [0000-0003-4822-7223], Watson, Christopher JE [0000-0002-0590-4901], Owen, Andrew [0000-0002-9819-7651], Vallier, Ludovic [0000-0002-3848-2602], Sampaziotis, Fotios [0000-0003-0812-7586], and Apollo - University of Cambridge Repository

Subjects
Transcription, Genetic, SARS-CoV-2, Ursodeoxycholic Acid, COVID-19, Reproducibility of Results, COVID-19 Drug Treatment, Liver Transplantation, Organoids, Mice, Nasal Mucosa, Liver, Cricetinae, UK-PBC Consortium, Animals, Humans, Receptors, Virus, Angiotensin-Converting Enzyme 2, Registries, Lung, Retrospective Studies
Abstract

Acknowledgements: We thank the European Association for the Study of the Liver (EASL) and the American Association for the Study of Liver Disease (AASLD) for supporting the COVID-Hep and SECURE-Liver registries; S. Marciniak and P. J. Lehner for comments and feedback on the manuscript; I. Goodfellow for providing the viral isolate; M. Wills and S. Clare for all their work ensuring a safe CL-3 working environment; C. Cormie for general lab support; the NIHR Cambridge BRC Cell Phenotyping Hub for their help with flow cytometry and processing of samples; the building staff of the Jeffrey Cheah Biomedical Centre for maintaining the institute open and safe during the period of lockdown; K. Füssel for coordinating the volunteer study and sample collection at the University Medical Centre Hamburg-Eppendorf; J. Hails, K.-I. Nikitopoulou and A. Ford for collecting blood samples; M. Colzani for advising on flow cytometry; A. Wiblin for advising on antibodies; and the Cambridge Biorepository for Translational Medicine for the provision of human tissue used in the study. T.B. was supported by an EASL Juan Rodès PhD fellowship. F.S. was supported by a UKRI Future Leaders fellowship, the Evelyn trust, an NIHR Clinical Lectureship, the Academy of Medical Sciences Starter Grant for Clinical Lecturers, the Addenbrooke’s Charitable Trust and the Rosetrees Trust. In addition, the F.S. laboratory is supported by the Cambridge University Hospitals National Institute for Health Research Biomedical Research Centre and the core support grant from the Wellcome Trust and Medical Research Council (MRC) of the Wellcome–Medical Research Council Cambridge Stem Cell Institute. The L.V. laboratory is funded by the ERC advanced grant New-Chol, the Cambridge University Hospitals National Institute for Health Research Biomedical Research Centre and the core support grant from the Wellcome Trust and MRC of the Wellcome–Medical Research Council Cambridge Stem Cell Institute. M.M., S.F. and G.D. are funded by the NIHR Cambridge Biomedical Research Centre and NIHR AMR Research Capital Funding Scheme (NIHR200640). The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. V.L.M. was funded by an MRC Clinical Research Training Fellowship. G.F.M. was funded by a post-doctoral fellowship from the National Institute for Health Research (NIHR) Rare Diseases–Translational Research Collaboration (RD-TRC) and by an MRC Clinical Academic Research Partnership (CARP) award. The UK-PBC Nested Cohort study was funded by an MRC Stratified Medicine award (MR/L001489/1). C.J.R.I. was supported by the Medical Research Council (MC_UU_12014). T.M. is funded by a Wellcome Trust Clinical Research Training Fellowship (102176/B/13/Z). The A.P.D. laboratory was supported by BHF TG/18/4/33770, Wellcome Trust 203814/Z/16/A and Addenbrooke’s Charitable Trust. The COVID-Hep.net registry was supported by the European Association for the Study of the Liver (EASL) and the SECURE-Liver registry was supported by the American Association for the Study of Liver Disease (AASLD). The lung perfusion experiment was supported by the National Institute for Health Research Blood and Transplant Research Unit (NIHR BTRU) in Organ Donation and Transplantation at Newcastle University and the University of Cambridge in partnership with NHS Blood and Transplant (NHSBT). The views expressed are those of the author(s) and not necessarily those of the NIHR, the Department of Health and Social Care or NHSBT. G.B. is funded by the European Reference Network for Hepatological Diseases (ERN RARE LIVER). A.O. acknowledges funding for preclinical research on treatment and prevention of COVID-19 from Unitaid (2020-38-LONGEVITY), the Engineering and Physical Sciences Research Council (EPSRC; EP/R024804/1), the Wellcome Trust (222489/Z/21/Z) and UK Research and Innovation (UKRI; BB/W010801/1). N.J.M. acknowledges funding from the MRC (CSF ref. MR/P008801/1 to N.J.M.), NHSBT (grant ref. WPA15-02 to N.J.M.) and Addenbrooke’s Charitable Trust (grant ref. to 900239 N.J.M.). This research was funded in whole, or in part, by the Wellcome Trust (203151/Z/16/Z, 203151/A/16/Z) and the UKRI Medical Research Council (MC_PC_17230). For the purpose of open access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission., Preventing SARS-CoV-2 infection by modulating viral host receptors, such as angiotensin-converting enzyme 2 (ACE2)1, could represent a new chemoprophylactic approach for COVID-19 that complements vaccination2,3. However, the mechanisms that control the expression of ACE2 remain unclear. Here we show that the farnesoid X receptor (FXR) is a direct regulator of ACE2 transcription in several tissues affected by COVID-19, including the gastrointestinal and respiratory systems. We then use the over-the-counter compound z-guggulsterone and the off-patent drug ursodeoxycholic acid (UDCA) to reduce FXR signalling and downregulate ACE2 in human lung, cholangiocyte and intestinal organoids and in the corresponding tissues in mice and hamsters. We show that the UDCA-mediated downregulation of ACE2 reduces susceptibility to SARS-CoV-2 infection in vitro, in vivo and in human lungs and livers perfused ex situ. Furthermore, we reveal that UDCA reduces the expression of ACE2 in the nasal epithelium in humans. Finally, we identify a correlation between UDCA treatment and positive clinical outcomes after SARS-CoV-2 infection using retrospective registry data, and confirm these findings in an independent validation cohort of recipients of liver transplants. In conclusion, we show that FXR has a role in controlling ACE2 expression and provide evidence that modulation of this pathway could be beneficial for reducing SARS-CoV-2 infection, paving the way for future clinical trials.

Published
2022

19. Cohort Profile: The National Institute for Health Research Health Informatics Collaborative: Hepatitis B Virus (NIHR HIC HBV) research dataset

Author

Wang, Tingyan, primary, Smith, David A, additional, Campbell, Cori, additional, Freeman, Oliver, additional, Moysova, Zuzana, additional, Noble, Theresa, additional, Várnai, Kinga A, additional, Harris, Steve, additional, Salih, Hizni, additional, Roadknight, Gail, additional, Little, Stephanie, additional, Glampson, Ben, additional, Mercuri, Luca, additional, Papadimitriou, Dimitri, additional, Jones, Christopher R, additional, Taylor, Vince, additional, Chaudhry, Afzal, additional, Phan, Hang, additional, Borca, Florina, additional, Olza, Josune, additional, Warricker, Frazer, additional, Romão, Luis, additional, Ramlakhan, David, additional, English, Louise, additional, Klenerman, Paul, additional, Andersson, Monique, additional, Collier, Jane, additional, Stockdale, Alexander J, additional, Todd, Stacy, additional, McIntyre, Karl, additional, Frankland, Andrew, additional, Nastouli, Eleni, additional, Khakoo, Salim I, additional, Gelson, William, additional, Cooke, Graham S, additional, Woods, Kerrie, additional, Davies, Jim, additional, Barnes, Eleanor, additional, and Matthews, Philippa C, additional

Published
2022
Full Text
View/download PDF

21. P137 Intraductal fully covered self-expanding metal stents in biliary strictures: a UK multicentre experience

Author

Ahmed, Wafaa, primary, Kyle, Dave, additional, Khanna, Amardeep, additional, Devlin, John, additional, Reffitt, David, additional, Zeino, Zeino, additional, Webster, George, additional, Phillpotts, Simon, additional, Gordon, Robert, additional, Corbett, Gareth, additional, Gelson, William, additional, Nayar, Manu, additional, Khan, Haider, additional, Cramp, Matthew, additional, Potts, Jonathan, additional, Fateen, Waleed, additional, Miller, Hamish, additional, Paranandi, Bharat, additional, Huggett, Matthew, additional, Everett, Simon M, additional, Hegade, Vinod S, additional, O’Kane, Rebecca, additional, Scott, Ryan, additional, McDougall, Neil, additional, Harrison, Phillip, additional, and Joshi, Deepak, additional

Published
2022
Full Text
View/download PDF

22. United Kingdom criteria for liver transplantation in the setting of isolated unresectable colorectal liver metastases.

Author

Murphy, Jamie, Prasad, Raj, Menon, Krishna, Adair, Anya, Parker, Ian, Berkman, Lindy, Gelson, William, Isaac, John, Jones, Rebecca, Manas, Derek, Middleton, Gary, Peddu, Praveen, Perera, Thamara, Pollok, Joerg‐Matthias, Scarsbrook, Andrew, and Zen, Yoh

Subjects
COLORECTAL liver metastasis, LIVER transplantation, COLORECTAL cancer, ONCOLOGIC surgery, KIDNEY transplantation
Abstract

Aim: Studies have demonstrated that liver transplantation may be an effective treatment for isolated unresectable colorectal cancer liver metastases (CRCLM). Published data suggest that 5‐year survival may be as high as 80%; however, recurrent disease is commonplace. Consequently, the Liver Transplantation for Unresectable Colorectal Liver Metastases Fixed Term Working Unit recommended to the NHS Blood and Transplant Liver Advisory Group that while CRCLM is an appropriate indication for transplantation, selection criteria should be conservative and that it should be undertaken within a clinical service evaluation programme. The aim of this work is to outline the proposed UK selection criteria and follow‐up process for CRCLM transplantation. Method: Consensus statement by colorectal cancer/liver transplantation patient representatives, experts in colorectal cancer surgery/oncology, liver transplantation surgery, hepatology, hepatobiliary radiology, hepatobiliary pathology and nuclear medicine. Results: This study provides a comprehensive outline of the inclusion/exclusion criteria for referral in the UK. Furthermore, the referral framework is also explained. Pretransplant assessment criteria for listing/delisting are outlined. Finally, the oncology‐specific outcome measures posttransplant are described. Conclusion: It is anticipated this service will begin in December 2022. A series of educational events for the referrers and transplant units will be arranged throughout 2023 to highlight CRCLM as a newly accepted UK indication for transplantation. A national audit will be undertaken to identify patients currently on treatment who meet the criteria for transplant. Data will be collected in a national registry and reviewed on an ongoing basis to confirm the safety of this treatment and to determine if the inclusion criteria require revision. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

23. Impact of the COVID-19 pandemic on routine surveillance for adults with chronic hepatitis B virus (HBV) infection in the UK

Author

Campbell, Cori, primary, Wang, Tingyan, additional, Smith, David A., additional, Freeman, Oliver, additional, Noble, Theresa, additional, Várnai, Kinga A, additional, Harris, Steve, additional, Salih, Hizni, additional, Roadknight, Gail, additional, Little, Stephanie, additional, Glampson, Ben, additional, Mercuri, Luca, additional, Papadimitriou, Dimitri, additional, Jones, Christopher R, additional, Taylor, Vince, additional, Chaudhry, Afzal, additional, Phan, Hang, additional, Borca, Florina, additional, Olza, Josune, additional, Warricker, Frazer, additional, Romão, Luis, additional, Ramlakhan, David, additional, English, Louise, additional, Klenerman, Paul, additional, Andersson, Monique I., additional, Collier, Jane, additional, Nastouli, Eleni, additional, Khakoo, Salim I., additional, Gelson, William, additional, Cooke, Graham S., additional, Woods, Kerrie, additional, Davies, Jim, additional, Barnes, Eleanor, additional, and Matthews, Philippa C., additional

Published
2022
Full Text
View/download PDF

24. Intraductal fully covered self-expanding metal stents in the management of post-liver transplant anastomotic strictures: a UK wide experience

Author

Ahmed, Wafaa, primary, Kyle, Dave, additional, Khanna, Amardeep, additional, Devlin, John, additional, Reffitt, David, additional, Zeino, Zeino, additional, Webster, George, additional, Phillpotts, Simon, additional, Gordon, Robert, additional, Corbett, Gareth, additional, Gelson, William, additional, Nayar, Manu, additional, Khan, Haider, additional, Cramp, Matthew, additional, Potts, Jonathan, additional, Fateen, Waleed, additional, Miller, Hamish, additional, Paranandi, Bharat, additional, Huggett, Matthew, additional, Everett, Simon M., additional, Hegade, Vinod S., additional, O’Kane, Rebecca, additional, Scott, Ryan, additional, McDougall, Neil, additional, Harrison, Phillip, additional, and Joshi, Deepak, additional

Published
2022
Full Text
View/download PDF

25. Impact of the COVID-19 pandemic on routine surveillance for adults with chronic hepatitis B virus (HBV) infection in the UK

Author

Campbell, Cori, primary, Wang, Tingyan, additional, Smith, David A, additional, Freeman, Oliver, additional, Noble, Theresa, additional, Várnai, Kinga A, additional, Harris, Steve, additional, Salih, Hizni, additional, Roadknight, Gail, additional, Little, Stephanie, additional, Glampson, Ben, additional, Mercuri, Luca, additional, Papadimitriou, Dimitri, additional, Jones, Christopher R, additional, Taylor, Vince, additional, Chaudhry, Afzal, additional, Phan, Hang, additional, Borca, Florina, additional, Olza, Josune, additional, Warricker, Frazer, additional, Romão, Luis, additional, Ramlakhan, David, additional, English, Louise, additional, Klenerman, Paul, additional, Andersson, Monique I., additional, Collier, Jane, additional, Nastouli, Eleni, additional, Khakoo, Salim I, additional, Gelson, William, additional, Cooke, Graham S, additional, Woods, Kerrie, additional, Davies, Jim, additional, Barnes, Eleanor, additional, and Matthews, Philippa C, additional

Published
2021
Full Text
View/download PDF

27. Cohort Profile: National Institute for Health Research Health Informatics Collaborative: Hepatitis B Virus (NIHR HIC HBV) Research Dataset

Author

Wang, Tingyan, primary, Smith, David A, additional, Campbell, Cori, additional, Freeman, Oliver, additional, Moysova, Zuzana, additional, Noble, Theresa, additional, Várnai, Kinga A, additional, Harris, Steve, additional, Salih, Hizni, additional, Roadknight, Gail, additional, Little, Stephanie, additional, Glampson, Ben, additional, Mercuri, Luca, additional, Papadimitriou, Dimitri, additional, Jones, Christopher R, additional, Taylor, Vince, additional, Chaudhry, Afzal, additional, Phan, Hang, additional, Borca, Florina, additional, Olza, Josune, additional, Warricker, Frazer, additional, Romão, Luis, additional, Ramlakhan, David, additional, English, Louise, additional, Klenerman, Paul, additional, Andersson, Monique, additional, Collier, Jane, additional, Nastouli, Eleni, additional, Khakoo, Salim I, additional, Gelson, William, additional, Cooke, Graham S, additional, Woods, Kerrie, additional, Davies, Jim, additional, Barnes, Eleanor, additional, and Matthews, Philippa C, additional

Published
2021
Full Text
View/download PDF

28. O07 FXR antagonists as new agents for COVID19

Author

Brevini, Teresa, primary, Maes, Mailis, additional, Webb, Gwilym J, additional, Gelson, William TH, additional, Forrest, Sally, additional, Mlcochova, Petra, additional, Dillon, Scott, additional, Varankar, Sagar, additional, Darvish-Damavandi, Mahnaz, additional, Mulcahy, Victoria L, additional, Kuc, Rhoda E, additional, Williams, Thomas L, additional, Galanakis, Vasileios, additional, Vila-Gonzalez, Marta, additional, Tysoe, Olivia C, additional, Muraro, Daniele, additional, Crozier, Thomas WM, additional, Bargehr, Johannes, additional, Sinha, Sanjay, additional, Upponi, Sara S, additional, Swift, Lisa, additional, Saeb-Parsy, Kourosh, additional, Davies, Susan E, additional, Marjot, Thomas, additional, Barnes, Eleanor, additional, Lohse, Ansgar W, additional, Moon, Andrew M, additional, Sidney Barritt, A, additional, Gupta, Ravindra K, additional, Baker, Stephen, additional, Davenport, Anthony P, additional, Corbett, Gareth, additional, Buczacki, Simon JA, additional, Lee, Joo-Hyeon, additional, Gibbs, Paul, additional, Butler, Andrew J, additional, Watson, Christopher JE, additional, Mells, George F, additional, Dougan, Gordon, additional, Vallier, Ludovic, additional, and Sampaziotis, Fotios, additional

Published
2021
Full Text
View/download PDF

30. FXR inhibition reduces ACE2 expression, SARS-CoV-2 infection and may improve COVID-19 outcome

Author

Brevini, Teresa, primary, Maes, Mailis, additional, Webb, Gwilym J., additional, Gelson, William T. H., additional, Forrest, Sally, additional, Mlcochova, Petra, additional, Dillon, Scott, additional, Varankar, Sagar, additional, Darvish-Damavandi, Mahnaz, additional, Mulcahy, Victoria L., additional, Kuc, Rhoda E., additional, Williams, Thomas L., additional, Galanakis, Vasileios, additional, Vila-Gonzalez, Marta, additional, Tysoe, Olivia C., additional, Muraro, Daniele, additional, Crozier, Thomas W. M., additional, Bargehr, Johannes, additional, Sinha, Sanjay, additional, Upponi, Sara S., additional, Swift, Lisa, additional, Saeb-Parsy, Kourosh, additional, Davies, Susan E., additional, Marjot, Thomas, additional, Barnes, Eleanor, additional, Lohse, Ansgar W., additional, Moon, Andrew M., additional, Sidney Barritt, A., additional, Gupta, Ravindra K., additional, Baker, Stephen, additional, Davenport, Anthony P., additional, Corbett, Gareth, additional, Buczacki, Simon J. A., additional, Lee, Joo-Hyeon, additional, Gibbs, Paul, additional, Butler, Andrew J., additional, Watson, Christopher J. E., additional, Mells, George F., additional, Dougan, Gordon, additional, Vallier, Ludovic, additional, and Sampaziotis, Fotios, additional

Published
2021
Full Text
View/download PDF

33. Cholangiocyte organoids can repair bile ducts after transplantation in the human liver

Author

Sampaziotis, Fotios, primary, Muraro, Daniele, additional, Tysoe, Olivia C., additional, Sawiak, Stephen, additional, Beach, Timothy E., additional, Godfrey, Edmund M., additional, Upponi, Sara S., additional, Brevini, Teresa, additional, Wesley, Brandon T., additional, Garcia-Bernardo, Jose, additional, Mahbubani, Krishnaa, additional, Canu, Giovanni, additional, Gieseck, Richard, additional, Berntsen, Natalie L., additional, Mulcahy, Victoria L., additional, Crick, Keziah, additional, Fear, Corrina, additional, Robinson, Sharayne, additional, Swift, Lisa, additional, Gambardella, Laure, additional, Bargehr, Johannes, additional, Ortmann, Daniel, additional, Brown, Stephanie E., additional, Osnato, Anna, additional, Murphy, Michael P., additional, Corbett, Gareth, additional, Gelson, William T. H., additional, Mells, George F., additional, Humphreys, Peter, additional, Davies, Susan E., additional, Amin, Irum, additional, Gibbs, Paul, additional, Sinha, Sanjay, additional, Teichmann, Sarah A., additional, Butler, Andrew J., additional, See, Teik Choon, additional, Melum, Espen, additional, Watson, Christopher J. E., additional, Saeb-Parsy, Kourosh, additional, and Vallier, Ludovic, additional

Published
2021
Full Text
View/download PDF

36. National Institute for Health Research Health Informatics Collaborative: development of a pipeline to collate electronic clinical data for viral hepatitis research

Author

Smith, David Anthony, primary, Wang, Tingyan, additional, Freeman, Oliver, additional, Crichton, Charles, additional, Salih, Hizni, additional, Matthews, Philippa Clare, additional, Davies, Jim, additional, Várnai, Kinga Anna, additional, Woods, Kerrie, additional, Jones, Christopher R., additional, Glampson, Ben, additional, Mulla, Abdulrahim, additional, Mercuri, Luca, additional, Shaw, A. Torm, additional, Drumright, Lydia N, additional, Romão, Luis, additional, Ramlakan, David, additional, Higgins, Finola, additional, Weir, Alistair, additional, Nastouli, Eleni, additional, Agarwal, Kosh, additional, Gelson, William, additional, Cooke, Graham S., additional, and Barnes, Eleanor, additional

Published
2020
Full Text
View/download PDF

38. Cholangiocyte organoids are plastic and their identity is controlled by their local microenvironment

Author

Sampaziotis, Fotis, primary, Muraro, Daniele, additional, Tysoe, Olivia C., additional, Beach, Timothy, additional, Sawiak, Stephen, additional, Godfrey, Edmund, additional, Upponi, Sara, additional, Wesley, Brandon, additional, Garcia-Bernardo, Jose, additional, Brevini, Teresa, additional, Mahbubani, Krishnaa, additional, Cannu, Giovanni, additional, Gieseck, Richard, additional, Berntsen, Natalie Lie, additional, Mulcahy, Victoria, additional, Crick, Keziah, additional, Fear, Corina, additional, Robinson, Sharayne, additional, Swift, Lisa, additional, Ortmann, Daniel, additional, Osnato, Anna, additional, Brown, Stephanie, additional, Murphy, Michael, additional, Gelson, William, additional, Mells, George, additional, Davies, Susan, additional, Amin, Irum, additional, Gibbs, Paul, additional, Teichmann, Sarah, additional, Butler, Andrew, additional, See, Teik Choon, additional, Melum, Espen, additional, Watson, Chris, additional, Saeb-Parsy, Kourosh, additional, and Vallier, Ludovic, additional

Published
2020
Full Text
View/download PDF

39. English hepatitis C registry data show high response rates to directly acting anti-virals, even if treatment is not completed

Author

Drysdale, Kathryn, primary, Ntuli, Yevedzo, additional, Bestwick, Jonathan, additional, Gelson, William, additional, Agarwal, Kosh, additional, Forton, Daniel, additional, Mutimer, David, additional, Elsharkawy, Ahmed M., additional, Townley, Ceri, additional, Mahomed, Faizel, additional, and Foster, Graham R., additional

Published
2020
Full Text
View/download PDF

40. National Institute for Health Research Health Informatics Collaborative (NIHR HIC): Development of a Pipeline to Collate Electronic Clinical Data for Viral Hepatitis Research

Author

Smith, David A, primary, Wang, Tingyan, additional, Freeman, Oliver, additional, Crichton, Charles, additional, Salih, Hizni, additional, Matthews, Philippa C, additional, Davies, Jim, additional, Várnai, Kinga A, additional, Woods, Kerrie, additional, Jones, Christopher R., additional, Glampson, Ben, additional, Mulla, Abdulrahim, additional, Mercuri, Luca, additional, Shaw, A. Torm, additional, Drumright, Lydia, additional, Romão, Luis, additional, Ramlakan, David, additional, Higgins, Finola, additional, Weir, Alistair, additional, Nastouli, Eleni, additional, Agarwal, Kosh, additional, Gelson, William, additional, Cooke, Graham S., additional, and Barnes, Eleanor, additional

Published
2019
Full Text
View/download PDF

49. Recurrence of Hepatitis B Infection in Liver Transplant Patients Receiving Long-Term Hepatitis B Immunoglobulin Prophylaxis

Author

Beckebaum, Susanne, Herzer, Kerstin, Bauhofer, Artur, Gelson, William, De Simone, Paolo, de Man, Robert, Engelmann, Cornelius, Müllhaupt, Beat, Vionnet, Julien, Salizzoni, Mauro, Volpes, Riccardo, Ercolani, Giorgio, De Carlis, Luciano, Angeli, Paolo, Burra, Patrizia, Dufour, Jean-François, Rossi, Massimo, Cillo, Umberto, Neumann, Ulf, Fischer, Lutz, Niemann, Gabriele, Toti, Luca, Tisone, Guiseppe, Beckebaum, Susanne, Herzer, Kerstin, Bauhofer, Artur, Gelson, William, De Simone, Paolo, de Man, Robert, Engelmann, Cornelius, Müllhaupt, Beat, Vionnet, Julien, Salizzoni, Mauro, Volpes, Riccardo, Ercolani, Giorgio, De Carlis, Luciano, Angeli, Paolo, Burra, Patrizia, Dufour, Jean-François, Rossi, Massimo, Cillo, Umberto, Neumann, Ulf, Fischer, Lutz, Niemann, Gabriele, Toti, Luca, and Tisone, Guiseppe

Abstract

BACKGROUND Long-term real-world data are relatively sparse regarding recurrence of chronic hepatitis B virus (HBV) infection after liver transplantation using hepatitis B immunoglobulin (HBIg) and nucleos(t)ide analogue (NUC) prophylaxis. MATERIAL AND METHODS Data from 371 adults transplanted for HBV-related disease at 20 European centers and given HBIg for ³12 months ± NUC therapy were analyzed retrospectively. RESULTS HBIg comprised Hepatect® (iv HBIgB; n=299), subcutaneous Zutectra® (sc HBIg, n=236), and other HBIg preparations (n=130); 93.5% received NUC therapy. Mean follow-up was 6.8±3.5 years. The primary efficacy variable, freedom from HBV recurrence, occurred in 95.7% of patients (95% CI [93.1%, 97.5%]). The observed incidence of recurrence was 16/371 (4.3%) (annual rate 0.65%); 5/16 patients with recurrence had discontinued HBIg and 7/16 had anti-HBs <100 IU/l. Excluding these 7 patients, the HBV recurrence rate was 2.4%. The recurrence rate while on HBIg therapy was 1 per 2069 months. In patients who discontinued HBIg, risk of HBV recurrence versus sc HBIg users was increased by 5.2-fold (1 per 1 603 versus 1 per 8379 treatment months). The annual rate of HBV-related hepatocellular carcinoma (HCC) recurrence was 1.7%. CONCLUSIONS These results support the long-term use of HBIg with NUC therapy as an effective management strategy to minimize risk of HBV recurrence and virus-related complications after liver transplantation.

Published
2018

50. Reconstruction of the mouse extrahepatic biliary tree using primary human extrahepatic cholangiocyte organoids

Author

Sampaziotis, Fotios, Justin, Alexander W., Tysoe, Olivia C., Sawiak, Stephen, Godfrey, Edmund M., Upponi, Sara S., Gieseck, Richard L., de Brito, Miguel Cardoso, Berntsen, Natalie Lie, Ortmann, Daniel, Yiangou, Loukia, Ross, Alexander, Bargehr, Johannes, Bertero, Alessandro, Pedersen, Marianne T., Pawlowski, Matthias, Valestrand, Laura, Madrigal, Pedro, Georgakopoulos, Nikitas, Pirmadjid, Negar, Skeldon, Gregor M., Casey, John, Shu, Wenmiao, Materek, Paulina M., Snijders, Kirsten, Brown, Stephanie, Rimland, Casey A., Simonic, Ingrid, Davies, Susan E., Jensen, Kim B., Zilbauer, Matthias, Gelson, William T.H., Alexander, Graeme J., Sinha, Sanjay, Hannan, Nicholas R.F., Wynn, Thomas A., Karlsen, Tom H., Melum, Espen, Markaki, Athina E., Saeb-Parsy, Kourosh, and Vallier, Ludovic

Subjects
Cholangiocytes, Bile duct, Bio-engineering, Tissue engineering, Organoids, Regenerative medicine, Cell-based therapy, Biliary atresia, PGA scaffold, Collagen scaffold, Densified collagen
Abstract

© 2017 Nature America, Inc., part of Springer Nature. All rights reserved. The treatment of common bile duct (CBD) disorders, such as biliary atresia or ischemic strictures, is restricted by the lack of biliary tissue from healthy donors suitable for surgical reconstruction. Here we report a new method for the isolation and propagation of human cholangiocytes from the extrahepatic biliary tree in the form of extrahepatic cholangiocyte organoids (ECOs) for regenerative medicine applications. The resulting ECOs closely resemble primary cholangiocytes in terms of their transcriptomic profile and functional properties. We explore the regenerative potential of these organoids in vivo and demonstrate that ECOs self-organize into bile duct-like tubes expressing biliary markers following transplantation under the kidney capsule of immunocompromised mice. In addition, when seeded on biodegradable scaffolds, ECOs form tissue-like structures retaining biliary characteristics. The resulting bioengineered tissue can reconstruct the gallbladder wall and repair the biliary epithelium following transplantation into a mouse model of injury. Furthermore, bioengineered artificial ducts can replace the native CBD, with no evidence of cholestasis or occlusion of the lumen. In conclusion, ECOs can successfully reconstruct the biliary tree, providing proof of principle for organ regeneration using human primary cholangiocytes expanded in vitro.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results